NL930009I2 - 6(R)-Ä2-(8'-Acyloxy-2'-methyl-6'-methyl (of waterstof)-poly-hydronafty-1')-ethylÜ-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen, de hydroxyzuurvorm van deze pyranonen, de farmaceutisch aanvardbare zouten van genoemde hydroxyzuren, en de door kleinealkyl- en fenyl-, dimethylamino- of acetylaminore sten gesubstitueerde klein-alkylesters van genoemdhydroxyzuur, werkwijzen ter bereiding ervan en ee n farmaceutisch antihypercholesterolemisch preparaat, dat dit bevat. - Google Patents

6(R)-Ä2-(8'-Acyloxy-2'-methyl-6'-methyl (of waterstof)-poly-hydronafty-1')-ethylÜ-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen, de hydroxyzuurvorm van deze pyranonen, de farmaceutisch aanvardbare zouten van genoemde hydroxyzuren, en de door kleinealkyl- en fenyl-, dimethylamino- of acetylaminore sten gesubstitueerde klein-alkylesters van genoemdhydroxyzuur, werkwijzen ter bereiding ervan en ee n farmaceutisch antihypercholesterolemisch preparaat, dat dit bevat.

Info

Publication number
NL930009I2
NL930009I2 NL930009C NL930009C NL930009I2 NL 930009 I2 NL930009 I2 NL 930009I2 NL 930009 C NL930009 C NL 930009C NL 930009 C NL930009 C NL 930009C NL 930009 I2 NL930009 I2 NL 930009I2
Authority
NL
Netherlands
Prior art keywords
hydroxy
methyl
lower alkyl
esters
hydroxy acid
Prior art date
Application number
NL930009C
Other languages
English (en)
Dutch (nl)
Other versions
NL930009I1 (nl
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL930009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/175,232 external-priority patent/US4293496A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NL930009I1 publication Critical patent/NL930009I1/nl
Publication of NL930009I2 publication Critical patent/NL930009I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
NL930009C 1980-02-04 1993-02-09 6(R)-Ä2-(8'-Acyloxy-2'-methyl-6'-methyl (of waterstof)-poly-hydronafty-1')-ethylÜ-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen, de hydroxyzuurvorm van deze pyranonen, de farmaceutisch aanvardbare zouten van genoemde hydroxyzuren, en de door kleinealkyl- en fenyl-, dimethylamino- of acetylaminore sten gesubstitueerde klein-alkylesters van genoemdhydroxyzuur, werkwijzen ter bereiding ervan en ee n farmaceutisch antihypercholesterolemisch preparaat, dat dit bevat. NL930009I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11804980A 1980-02-04 1980-02-04
US11805180A 1980-02-04 1980-02-04
US17546080A 1980-08-05 1980-08-05
US06/175,232 US4293496A (en) 1980-02-04 1980-08-05 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones

Publications (2)

Publication Number Publication Date
NL930009I1 NL930009I1 (nl) 1993-04-01
NL930009I2 true NL930009I2 (nl) 1993-09-16

Family

ID=27494171

Family Applications (1)

Application Number Title Priority Date Filing Date
NL930009C NL930009I2 (nl) 1980-02-04 1993-02-09 6(R)-Ä2-(8'-Acyloxy-2'-methyl-6'-methyl (of waterstof)-poly-hydronafty-1')-ethylÜ-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen, de hydroxyzuurvorm van deze pyranonen, de farmaceutisch aanvardbare zouten van genoemde hydroxyzuren, en de door kleinealkyl- en fenyl-, dimethylamino- of acetylaminore sten gesubstitueerde klein-alkylesters van genoemdhydroxyzuur, werkwijzen ter bereiding ervan en ee n farmaceutisch antihypercholesterolemisch preparaat, dat dit bevat.

Country Status (22)

Country Link
EP (1) EP0033538B1 (enExample)
AU (1) AU548996B2 (enExample)
CA (1) CA1199322A (enExample)
CY (1) CY1404A (enExample)
DD (1) DD155989A5 (enExample)
DE (1) DE3173042D1 (enExample)
DK (1) DK157292C (enExample)
ES (1) ES8609296A1 (enExample)
FI (1) FI78082C (enExample)
GR (1) GR74798B (enExample)
HK (1) HK16488A (enExample)
IE (1) IE51478B1 (enExample)
IL (1) IL62044A (enExample)
MA (1) MA19054A1 (enExample)
MY (1) MY8700745A (enExample)
NL (1) NL930009I2 (enExample)
NO (2) NO154229C (enExample)
NZ (1) NZ196172A (enExample)
PT (1) PT72441B (enExample)
RO (1) RO82367B (enExample)
SG (1) SG61087G (enExample)
YU (1) YU28181A (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692381B2 (ja) * 1980-03-31 1994-11-16 三共株式会社 Ｍｂ−５３０ａ誘導体
US4432996A (en) * 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
US4343814A (en) * 1980-11-17 1982-08-10 Merck & Co., Inc. Hypocholesterolemic fermentation products
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
PT77996B (en) * 1983-01-24 1986-05-30 Sandoz Sa Process of the preparations of mevalonelactone analogs and derivatives thereof and of pharmaceutical compositions containing them
EP0137444B1 (en) * 1983-10-11 1990-01-31 Merck & Co. Inc. Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-Decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
DE3480923D1 (de) * 1983-10-11 1990-02-08 Merck & Co Inc Verfahren zur c-methylierung von 2-methylbutyraten.
US4668699A (en) * 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
EA000954B1 (ru) * 1995-12-06 2000-08-28 Балканфарма - Разград Ад Способ получения ловастатина
CA2185961A1 (en) 1996-09-19 1998-03-20 K.S. Keshava Murthy Process for producing simvastatin
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
SI9800057A (sl) * 1998-02-26 1999-08-31 Krka, Tovarna Zdravil, D.D. Postopek za pripravo simvastatina in njegovih derivatov
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
CA2356422C (en) 1998-12-23 2008-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
HUP0104745A3 (en) 1998-12-23 2003-01-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
CZ20012342A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace
ES2201827T3 (es) 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de derivados de acido fibrico para indicaciones cardiovasculares.
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
CZ303774B6 (cs) 2000-09-07 2013-05-02 Kaneka Corporation Zpusob krystalizace hydroxykarboxylové kyseliny
MXPA04003524A (es) 2001-11-02 2004-07-23 Searle Llc Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
SI21187A (sl) 2002-03-26 2003-10-31 Krka, Tovarna Zdravil D.D., Novo Mesto Postopek za pripravo 4-oksitetrahidropiran-2-onov
KR20040092790A (ko) * 2003-04-29 2004-11-04 씨제이 주식회사 심바스타틴 중간체 제조방법
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
RS53084B (sr) 2006-07-05 2014-06-30 Takeda Gmbh Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4, kao što je roflumilast, roflumilast-n-oksid za lečenje inflamatornih plućnih obolenja
WO2009013764A2 (en) * 2007-07-24 2009-01-29 Jubilant Organosys Limited Process for producing 6(r)-[2-(8'(s)-2 ',2 '-dimethylbutyryloxy-2'(s),6'(r)-dimethyl-1,2,6,7', 8',8a'(r)- hexahydronaphthyl-l'(s))ethyl]-4(r)-hydroxy-3,4,5,6- tetrahydro-2h-pyran-2-one
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
ES2343049B1 (es) 2008-10-15 2011-06-10 Neuron Biopharma, S.A. Biosintesis de derivados de monacolina j.
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2241561A1 (en) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
EP2797641B1 (en) 2011-12-29 2019-07-10 Trustees Of Tufts College Functionalization of biomaterials to control regeneration and inflammation responses
MX2014014830A (es) 2012-06-15 2015-05-11 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (enExample) 1974-06-07 1981-03-18
US4049495A (en) 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
DE2748825C2 (de) 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
JPS6026094B2 (ja) 1978-07-04 1985-06-21 三共株式会社 テトラヒドロｍｌ↓−２３６ｂおよびその誘導体並びにそれを有効成分とする高脂血症治療剤
JPS5925599B2 (ja) * 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
IL60219A (en) * 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them
PT72394B (en) 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics

Also Published As

Publication number Publication date
CY1404A (en) 1988-04-22
MA19054A1 (fr) 1981-10-01
RO82367B (ro) 1984-02-28
NO1994001I1 (no) 1994-07-01
DD155989A5 (de) 1982-07-21
CA1199322A (en) 1986-01-14
IE810204L (en) 1981-08-04
NL930009I1 (nl) 1993-04-01
HK16488A (en) 1988-03-11
PT72441B (pt) 1984-08-01
DK157292C (da) 1990-05-07
NO810358L (no) 1981-08-05
SG61087G (en) 1987-10-23
EP0033538B1 (en) 1985-11-27
IL62044A0 (en) 1981-03-31
EP0033538A2 (en) 1981-08-12
DE3173042D1 (en) 1986-01-09
FI810287L (fi) 1981-08-05
FI78082C (fi) 1989-06-12
AU6657381A (en) 1981-08-13
MY8700745A (en) 1987-12-31
YU28181A (en) 1983-10-31
RO82367A (ro) 1984-02-21
IE51478B1 (en) 1987-01-07
AU548996B2 (en) 1986-01-09
ES499079A0 (es) 1985-10-16
EP0033538A3 (en) 1982-02-24
FI78082B (fi) 1989-02-28
NZ196172A (en) 1985-01-31
GR74798B (enExample) 1984-07-12
NO154229C (no) 1986-08-13
ES8609296A1 (es) 1985-10-16
DK157292B (da) 1989-12-04
IL62044A (en) 1987-03-31
PT72441A (pt) 1981-03-01
NO154229B (no) 1986-05-05
DK46181A (da) 1981-08-05

Similar Documents

Publication Publication Date Title
NL930009I2 (nl) 6(R)-Ä2-(8'-Acyloxy-2'-methyl-6'-methyl (of waterstof)-poly-hydronafty-1')-ethylÜ-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen, de hydroxyzuurvorm van deze pyranonen, de farmaceutisch aanvardbare zouten van genoemde hydroxyzuren, en de door kleinealkyl- en fenyl-, dimethylamino- of acetylaminore sten gesubstitueerde klein-alkylesters van genoemdhydroxyzuur, werkwijzen ter bereiding ervan en ee n farmaceutisch antihypercholesterolemisch preparaat, dat dit bevat.
DE3165894D1 (en) 6(r)-(2-(8'-etherified-hydroxy-2',6'-dimethylpolyhydro-naphthyl-1')-ethyl)-4(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-ones, the hydroxy acid form of said pyranones, the salts of said acid form, process for preparing the same and an antihypercholesterolemic pharmaceutical composition containing the same
GB2210879B (en) 4h-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
AU1331588A (en) Method for treatment of alcohol abuse
CA2216623A1 (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
DE3486409D1 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
JPS57185275A (en) Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
KR970702291A (ko) 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin)
AU4603293A (en) Antiperspirant actives and compositions
EP0743308A3 (en) Quinazoline compound and anti-tumor agent containing said compound as an active ingredient
EP0974349A4 (en) ATHLETIC ENDURANCE INCREASING AGENT
DK0416804T3 (da) Præparat til udvortes administration
ITTO920532A0 (it) Procedimento per la preparazione di delta lattoni saturi per bioidro-genazione dei corrispondenti composti insaturi naturali mediante microrganismi.
FR2694558B1 (fr) Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
ES2000681A6 (es) Un procedimiento para preparar nuevos compuestos de bencilpiperazina
KE3746A (en) 6(r)-(2-(8'-acyloxy-2'-methyl-6'-methyl(or hydrogen)-polyhydronaphthyl-1')-ethyl)-4(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-ones,the hydroxy acid form of said pyranones,the pharmaceutically acceptable salts of said hydroxy acids,and the lower alkyl,and phenyl,dimethylamino or acetylamino substituted lower alkyl esters of said hydroxy acid,processes for preparing the same, and a pharmaceutical antihypercholesterolemic composition containing the same
JPS57185276A (en) Dihydro-dum-4 and dihydro-isodum-4 and their derivative
IE820912L (en) Controlling ureaplasma infections
GR79114B (enExample)
AU565723B2 (en) 1,3-bis(dimethylamino)-2-propyl-4-chlorophenoxy-acetate
IT8219944A0 (it) Procedimento per preparare sali di addizione di acidi di 3,4-diacilossi-alfa-parentesi aperta (metilammino)-metilparentesi quadra chiusa -benzilalcool.
JPS56110618A (en) Remedy for disease of excess serum lipoperoxide
SE9601483D0 (sv) Beredning av komposition
IL77922A (en) 1,4-dihalogenobutane-2,3-diones,their preparation and their use as intermediate for producing 2-(2-aminothiazol-4-yl)glyoxylic acid derivatives or a salt thereof
IT8819400A0 (it) Composizioni aminoacidiche perfezionate per il trattamento specifico delle insufficienze multiple d'organo.